Pfizer says money killed AZ deal

Share this article:

Pfizer Chief Financial Officer Frank D'Amelio told an audience at a Goldman Sachs investment conference that the AstraZeneca deal fell apart over money, Bloomberg reports.

AstraZeneca turned down the $117 billion bid Memorial Day weekend, and Pfizer cannot approach the company until three months have lapsed.

Bloomberg reported earlier that perceived personal affronts also doomed Pfizer's overture.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

DOJ closes Brilinta investigation

AstraZeneca announced the end of the investigation Tuesday.

Doctors back unique biosimilar names

A host of doctors has asked FDA Commissioner Margaret Hamburg to back a naming convention that would require biologics and biosimilars to have different names.

Roche has no rights to Sovaldi, panel rules

Despite a collaboration with original Sovaldi owner Pharmasset in 2004, a panel ruled Roche has no rights to HCV treatment Sovaldi.